EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)Open Access · CC BY-NC 4.0

Single-cell dissection of persistent tumor antigens in non-responders reveals opportunities for TAA-targeted vaccination after neoadjuvant therapy in esophageal squamous cell carcinoma

Ruixiang Zhang iD, Shu Qi iD, Yang Zhou, Ying Hu, Yang Li, Yue Li, Jianjun Qin, Ai-Rong Yang, Henghui Zhang, Zhihua Liu, Yin Li iD

Journal for ImmunoTherapy of Cancer · 2026

DOI: 10.1136/jitc-2025-014562 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2026. Verfasst von Ruixiang Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Section of Esophageal and Mediastinal Oncology, Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/C…. Hauptthemen laut MEDLINE: Antigens, Neoplasm, Antineoplastic Combined Chemotherapy Protocols, Cancer Vaccines, Esophageal Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Fundamental Research Funds for the Central Universities, Beijing Xisike Clinical Oncology Research Foundation, National Science and Technology Major Project of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Neoadjuvant immune checkpoint blockade (ICB) combined with chemotherapy has demonstrated higher response rates than chemotherapy alone in resectable esophageal squamous cell carcinoma (ESCC). Although tumor microenvironment (TME) features associated with treatment response have been studied in the contexts of both chemotherapy and immunotherapy, direct comparisons of these characteristics and their implications for novel therapeutic development remain largely unexplored.

Methods

Paired pretreatment and post-treatment tumor samples were prospectively collected from 55 patients with locally advanced ESCC enrolled in a multicenter, phase 3 clinical trial (ChiCTR2000040034). Patients were randomized to receive neoadjuvant chemotherapy (paclitaxel with cisplatin, TP; n=14) or its combination with PD-1 blockade (camrelizumab, albumin-bound paclitaxel and cisplatin/paclitaxel and cisplatin, Cam+nab-TP/TP; n=41), followed by surgical resection. Pathological response was defined based on Mandard’s Tumor Regression Grade scoring system. Changes in immune cell populations and tumor-associated antigens (TAAs) within the TME in relation to response were characterized using single-cell RNA and T cell receptor sequencing.

Results

Both chemotherapy and chemoimmunotherapy responders exhibited shared temporal dynamics including dendritic cell remodeling, cytotoxic CD8 + T cell contraction, and memory T cell expansion, with chemoimmunotherapy uniquely suppressing the clonal expansion of GZMB + TIGIT + T cells. In contrast, non-responders failed to elicit effective antitumor immunity and displayed persistent expression of targetable TAAs, fully preserved HLA machinery, and clonal expansion of dysfunctional GZMB + TIGIT + T cells.

Conclusions

Our study identifies key immune contributors correlated with response to neoadjuvant therapies and a panel of TAAs in non-responders. These findings support the development of TAA-targeted therapeutic vaccines and combination strategies incorporating ICB to overcome resistance in non-responders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigens, NeoplasmAntineoplastic Combined Chemotherapy ProtocolsCancer VaccinesEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaNeoadjuvant TherapyAgedFemaleHumansMaleMiddle AgedTumor Microenvironment

Stichwörter der Autor:innen

Esophageal CancerImmune Checkpoint InhibitorPathologic non responseTumor microenvironment - TMEVaccine

Substanzen

Antigens, NeoplasmCancer Vaccines

Autor:innen und Institutionen

  • Section of Esophageal and Mediastinal Oncology, Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union M…
  • State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Beijing Immupeutics Medicine Technology Limited, Beijing, China.
  • Biomedical Innovation Center, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
  • Beijing Cell Therapy Translational Institute, Beijing, China.
  • Biomedical Innovation Center, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Beijing Shijitan Hospital, Capital Medical University, Beijing, China zhhbao@ccmu.edu.cn.

ORCID-Profile: Ruixiang Zhang, Shu Qi, Yin Li

Förderung

  • Fundamental Research Funds for the Central Universities
  • Beijing Xisike Clinical Oncology Research Foundation
  • National Science and Technology Major Project of China
  • Special Program for Basic Resource Survey of the Ministry of Science and Technology
  • Beijing Natural Science Foundation
  • National Natural Science Foundation of China

Zitieren

APA

Zhang, R., Qi, S., Zhou, Y., Hu, Y., Li, Y., Li, Y., Qin, J., Yang, A. R., Zhang, H., Liu, Z., & Li, Y. (2026). Single-cell dissection of persistent tumor antigens in non-responders reveals opportunities for TAA-targeted vaccination after neoadjuvant therapy in esophageal squamous cell carcinoma. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2025-014562

Vancouver

Zhang R, Qi S, Zhou Y, Hu Y, Li Y, Li Y, et al. Single-cell dissection of persistent tumor antigens in non-responders reveals opportunities for TAA-targeted vaccination after neoadjuvant therapy in esophageal squamous cell carcinoma. Journal for ImmunoTherapy of Cancer. 2026. doi:10.1136/jitc-2025-014562

BibTeX
@article{Zhang2026,
  author = {Zhang, Ruixiang and Qi, Shu and Zhou, Yang and Hu, Ying and Li, Yang and Li, Yue and Qin, Jianjun and Yang, Ai-Rong and Zhang, Henghui and Liu, Zhihua and Li, Yin},
  title = {Single-cell dissection of persistent tumor antigens in non-responders reveals opportunities for TAA-targeted vaccination after neoadjuvant therapy in esophageal squamous cell carcinoma},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  doi = {10.1136/jitc-2025-014562}
}
Kostenlos starten →